File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Is Risk-Assessment-and-Management-Programme for primary care patients with Hypertension (RAMP-HT) cost-effective?
Title | Is Risk-Assessment-and-Management-Programme for primary care patients with Hypertension (RAMP-HT) cost-effective? |
---|---|
Authors | |
Issue Date | 2018 |
Publisher | The Hong Kong College of Family Physicians. |
Citation | Hong Kong Primary Care Conference 2018: Family Physician – Nexus of the New Era of Primary Care, Hong Kong, 23–24 June 2018. In Programme Book, p. 65 How to Cite? |
Abstract | INTRODUCTION The multi-disciplinary Risk-Assessment-and-Management-Programme for patients with hypertension (RAMP-HT) integrated into usual care was effective in improving blood pressure (BP) control and reducing 10-year predicted cardiovascular disease (CVD) risk of primary care hypertensive (HT) patients after 12 months. This study aimed to assess the long-term cost-effectiveness of the RAMP-HT after 5 years. METHODS A territory-wide prospective cohort was conducted on 58,514 RAMP-HT participants matched by propensity score with the same number of HT patients managed by General-Out-Patient-Clinics (GOPC) between October 2011 and September 2013. All subjects were aged ≥18years without previous clinical diagnosis of CVD or end-stage renal disease (ESRD). RAMP-HT costs included set-up cost, administrative cost, and the number of RAMP-HT interventions used multiplied by unit cost. RAMP-HT effectiveness was estimated by 5-year cumulative incidence of developing complications and all-cause mortality. RAMP-HT cost-effectiveness was reflected by Incremental-Cost-Effectiveness Ratio (ICER) and program costs per event prevented. RESULTS RAMP-HT significantly reduced incidences of CVD (9.0% vs 14.1%, p<0.001), ESRD (1.3% vs 2.3%, p<0.001) and all-cause mortality (5.3% vs 10.9%, p<0.001), compared to usual care. The 5-year average RAMP-HT cost was US$63 per participant. The RAMP-HT costed US$1,242, US$6,732 and US$1,333 to reduce one CVD, ESRD and death over 5 years, respectively. DISCUSSION The encouraging results confirmed that RAMP-HT was cost-effective in preventing HT-related complications and mortality up to 5 years. Further study should be conducted to evaluate the lifetime cost-effectiveness of the RAMP-HT to confirm the sustainability of RAMP-HT and its actual impact on healthcare services and resources. |
Description | Poster Presentation - no. 002 |
Persistent Identifier | http://hdl.handle.net/10722/263862 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, YTE | - |
dc.contributor.author | Wan, EYF | - |
dc.contributor.author | Tang, EHM | - |
dc.contributor.author | Ho, SY | - |
dc.contributor.author | Lam, CLK | - |
dc.date.accessioned | 2018-10-22T07:45:38Z | - |
dc.date.available | 2018-10-22T07:45:38Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Hong Kong Primary Care Conference 2018: Family Physician – Nexus of the New Era of Primary Care, Hong Kong, 23–24 June 2018. In Programme Book, p. 65 | - |
dc.identifier.uri | http://hdl.handle.net/10722/263862 | - |
dc.description | Poster Presentation - no. 002 | - |
dc.description.abstract | INTRODUCTION The multi-disciplinary Risk-Assessment-and-Management-Programme for patients with hypertension (RAMP-HT) integrated into usual care was effective in improving blood pressure (BP) control and reducing 10-year predicted cardiovascular disease (CVD) risk of primary care hypertensive (HT) patients after 12 months. This study aimed to assess the long-term cost-effectiveness of the RAMP-HT after 5 years. METHODS A territory-wide prospective cohort was conducted on 58,514 RAMP-HT participants matched by propensity score with the same number of HT patients managed by General-Out-Patient-Clinics (GOPC) between October 2011 and September 2013. All subjects were aged ≥18years without previous clinical diagnosis of CVD or end-stage renal disease (ESRD). RAMP-HT costs included set-up cost, administrative cost, and the number of RAMP-HT interventions used multiplied by unit cost. RAMP-HT effectiveness was estimated by 5-year cumulative incidence of developing complications and all-cause mortality. RAMP-HT cost-effectiveness was reflected by Incremental-Cost-Effectiveness Ratio (ICER) and program costs per event prevented. RESULTS RAMP-HT significantly reduced incidences of CVD (9.0% vs 14.1%, p<0.001), ESRD (1.3% vs 2.3%, p<0.001) and all-cause mortality (5.3% vs 10.9%, p<0.001), compared to usual care. The 5-year average RAMP-HT cost was US$63 per participant. The RAMP-HT costed US$1,242, US$6,732 and US$1,333 to reduce one CVD, ESRD and death over 5 years, respectively. DISCUSSION The encouraging results confirmed that RAMP-HT was cost-effective in preventing HT-related complications and mortality up to 5 years. Further study should be conducted to evaluate the lifetime cost-effectiveness of the RAMP-HT to confirm the sustainability of RAMP-HT and its actual impact on healthcare services and resources. | - |
dc.language | eng | - |
dc.publisher | The Hong Kong College of Family Physicians. | - |
dc.relation.ispartof | Hong Kong Primary Care Conference 2018 | - |
dc.title | Is Risk-Assessment-and-Management-Programme for primary care patients with Hypertension (RAMP-HT) cost-effective? | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Yu, YTE: ytyu@hku.hk | - |
dc.identifier.email | Wan, EYF: yfwan@hku.hk | - |
dc.identifier.email | Tang, EHM: erichm@hku.hk | - |
dc.identifier.email | Ho, SY: soki0721@hku.hk | - |
dc.identifier.email | Lam, CLK: clklam@hku.hk | - |
dc.identifier.authority | Yu, YTE=rp01693 | - |
dc.identifier.authority | Lam, CLK=rp00350 | - |
dc.identifier.hkuros | 293950 | - |
dc.identifier.spage | 65 | - |
dc.identifier.epage | 65 | - |
dc.publisher.place | Hong Kong | - |